Business Context and Reporting Period
Company: Mainz Biomed N.V. (Note: Input metadata referenced "Quantum Cyber N.V.", but the filing text identifies the registrant as Mainz Biomed N.V., trading as MYNZ on Nasdaq).
Reporting Period: Fiscal year ended December 31, 2024.
Business Overview: Mainz Biomed is an early-stage biotechnology company developing in-vitro diagnostic (IVD) tests for early cancer detection. Its flagship product, ColoAlert, is a stool-based colorectal cancer (CRC) screening test marketed in Europe. The company is developing a next-generation CRC product for the U.S. market and a pancreatic cancer screening test (PancAlert). In 2024, the company ceased direct-to-consumer sales to focus on distributing IVD kits to third-party laboratories in Europe.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $893,991 | $895,479 |
| Gross Profit | $574,883 | $509,659 |
| Gross Margin | 64% | 57% |
| Net Loss | $(21,650,663) | $(26,295,727) |
| Operating Cash Flow | $(17,090,011) | $(21,938,845) |
| Cash and Equivalents (End of Period) | $6,235,670 | $7,070,925 |
| Accumulated Deficit | $(90,978,684) | $(69,328,021) |
| Convertible Debt (Fair Value) | $1,021,000 | $4,859,000 |
Material Changes vs. Prior Period
- Revenue Stability: Total revenue remained flat ($893,991 vs. $895,479) due to a strategic shift. Lab network sales increased 33% to $562,507, while direct-to-consumer sales decreased 34% to $272,813 as the company exited that channel.
- Expense Reduction: Total operating expenses decreased 29% to $19.27 million.
- R&D: Decreased 39% to $5.84 million, primarily due to lower clinical study costs ($1.0M in 2024 vs. $4.3M in 2023).
- G&A: Decreased 42% to $6.57 million, driven by a $3.1 million reduction in non-cash stock option expense and lower professional fees.
- Restructuring: The company incurred $277,160 in restructuring expenses in 2024 (nil in 2023) related to a 65% reduction in personnel, executive salary reductions, and the sale of its European Oncology Lab business.
- Other Income/Expense: Net other expense increased significantly to $2.96 million (from income of $0.35M in 2023), driven by a $2.05 million non-cash fair value adjustment on convertible debt.
Outlook, Risks, and Management Commentary
- Going Concern: The auditor's report includes an explanatory paragraph indicating substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows. Management plans to fund operations through existing cash ($6.2M) and future equity/debt financings.
- Strategic Focus: Management is prioritizing the expansion of the ColoAlert lab network in Europe and preparing for the "reconAAsense" pivotal clinical study in the U.S. to seek FDA approval for the next-generation CRC product.
- Regulatory Risks: Success depends heavily on obtaining FDA market authorization (PMA) for the U.S. market and maintaining CE-IVD compliance in Europe under new regulations (IVDR).
- Legal Proceedings: The company is involved in litigation with a former underwriter (Boustead Securities) regarding breach of contract and unpaid compensation. The outcome is uncertain, and no loss estimate can be made.
- Market Risk: The company faced Nasdaq minimum bid price compliance issues in 2024, requiring a 1-for-40 reverse stock split in December 2024 to regain compliance.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $6.2 million cash balance against the projected burn rate, given the "substantial doubt" going concern warning.
- Convertible Debt Terms: Review the terms of the Pre-Paid Advance Agreement (PPA) and convertible notes, specifically the "Trigger Event" clauses that could force monthly cash payments if the stock price falls below the floor price.
- Customer Concentration: Confirm the stability of the single customer that accounted for 57% of 2024 revenue.
- Regulatory Milestones: Monitor the timeline and results of the "reconAAsense" U.S. pivotal study, which is critical for future revenue growth.
- Legal Resolution: Track the status of the lawsuit against Boustead Securities and the arbitration proceedings.